Asset Details
Do you wish to reserve the book?
ELK4 transcription promotes MSI2‐mediated progression of non‐small cell lung cancer through the TGF‐β/SMAD3 pathway
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ELK4 transcription promotes MSI2‐mediated progression of non‐small cell lung cancer through the TGF‐β/SMAD3 pathway
Do you wish to request the book?
ELK4 transcription promotes MSI2‐mediated progression of non‐small cell lung cancer through the TGF‐β/SMAD3 pathway
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ELK4 transcription promotes MSI2‐mediated progression of non‐small cell lung cancer through the TGF‐β/SMAD3 pathway
2025
Overview
Non‐small cell lung cancer (NSCLC) is a primary contributor to global cancer‐related mortality. Musashi‐2 (MSI2), an RNA‐binding protein (RBP), is upregulated in specific NSCLC tumor subgroups. The current investigation evaluated the role and underlying mechanism of MSI2 in NSCLC. The expression levels of ELK4, MSI2, SMAD3, p‐SMAD3 and TGFβR1 were assessed via RT–qPCR or Western blot. Chromatin immunoprecipitation (ChIP) and dual luciferase reporter assays were used to confirm the interaction between ELK4 and MSI2. The proliferation, migration and invasion of NSCLC cells were determined via MTT, colony formation, and transwell assays, respectively. A xenograft tumor model was established in BALB/c nude mice. Immunohistochemical (IHC) staining was used to test Ki67 expression. We found that MSI2 and ELK4 expression levels were increased in NSCLC tissues and cells. ELK4 depletion suppressed the proliferation, migration and invasion of NSCLC cells. ELK4 acts as a transcription factor and promotes the transcription of MSI2. MSI2 depletion repressed NSCLC cell proliferation, migration and invasion through the TGF‐β/SMAD3 pathway. Overexpression of ELK4 reversed the inhibitory effect of MSI2 repression on NSCLC progression. These results confirmed that ELK4 is a direct regulator of MSI2 expression and that MSI2 promotes NSCLC progression through TGF‐β/SMAD3 activation, suggesting the potential clinical value of inhibiting MSI2 in NSCLC.
Publisher
Wiley Publishing Asia Pty Ltd,John Wiley & Sons, Inc,Wiley
Subject
/ Animals
/ Biopsy
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Carcinoma, Non-Small-Cell Lung - metabolism
/ Carcinoma, Non-Small-Cell Lung - pathology
/ Cell Proliferation - genetics
/ Cells
/ ELK4
/ Ethics
/ Female
/ Gene Expression Regulation, Neoplastic
/ Humans
/ Male
/ Mice
/ MSI2
/ Original
/ Proteins
/ RNA-Binding Proteins - genetics
/ RNA-Binding Proteins - metabolism
/ SMAD3
/ TGF‐β
